Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Laryngoscope ; 131(2): E665-E670, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-32640082

RESUMEN

OBJECTIVE: Leptin hormone plays an important role in metabolic control and is elevated in obstructive sleep apnea (OSA). The aim of this study was to assess the hypothesis that surgical treatment will reduce leptin levels in OSA patients. STUDY DESIGN: Prospective study. SUBJECTS AND METHODS: Twenty-three patients with multilevel OSA underwent modified genioglossus muscle advancement with anterolateral advancement pharyngoplasty between April 2018 and September 2019. Serum leptin level was measured preoperatively and 3 months postoperatively for all patients and 18 control subjects. All patients were evaluated before and 3 months after surgery by history taking, clinical examination, polysomnography, cephalometry, and Epworth Sleepiness Scale. RESULTS: Preoperatively, patients with OSA had a higher Leptin level (18.46 ± 4.73 ng/mL) than did control subjects (7.07 ± 1.26 ng/mL) (P < .001). Surgery resulted in a significant reduction in the level of leptin from 18.46 ± 4.73 ng/mL to 8.03 ± 2.22 ng/mL (P < .001). Reductions in leptin level was correlated with changes in apnea hypopnea index (AHI) (r = 0.61, P = .002) and minimum oxygen saturation (SaO2) (r = -0.54, P = .008). CONCLUSION: Effective multilevel surgery in the form of modified genioglossus muscle advancement with anterolateral advancement pharyngoplasty could significantly reduce leptin level in OSA patients and this reduction is correlated with the degree of OSA improvement in term of AHI and SaO2. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E665-E670, 2021.


Asunto(s)
Leptina/sangre , Apnea Obstructiva del Sueño/cirugía , Adulto , Humanos , Masculino , Persona de Mediana Edad , Faringe/cirugía , Polisomnografía , Estudios Prospectivos , Apnea Obstructiva del Sueño/sangre , Lengua/cirugía
2.
J Bras Nefrol ; 38(4): 403-410, 2016 Dec.
Artículo en Portugués, Inglés | MEDLINE | ID: mdl-28001185

RESUMEN

INTRODUCTION: Early detection diabetic nephropathy (DN) is important. Whether serum uric acid (SUA) has a role in the development of DN is not known. OBJECTIVE: To study the relationship between SUA and hypertension, early nephropathy and progression of chronic kidney disease (CKD) in type 2 diabetes mellitus (T2DM). METHODS: The total number of the study was 986 participants, according to presence and duration of diabetes were classified into three groups. Group I; including 250 healthy participants. Group II; including 352 with onset of diabetes < 5 years. Group III; including 384, with the onset of diabetes > 5 years. All participants were submitted to complete clinical examination, anthropometric measurements, laboratory investigations, including glycosylated hemoglobin (HbA1C), as well triglycerides to high-density lipoprotein ratios (TG/HDL-C), SUA, urinary albumin/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR). RESULTS: SUA, BP, HbA1c, TG/HDL-C ratio, and ACR levels were significantly higher in group III than group I, II and in II than I. eGFR significantly lower in group III than group I, II and in II than I (p < 0.001). Age, BMI, BP, HbA1c, TG/HDL-C, ACR, were positively correlated with SUA, while GFR negatively correlated. SUA at level of > 6.1 mg/dl, > 6.2 mg/dl and > 6.5 mg/dl had a greater sensitivity and specificity for identifying hypertension, early nephropathy and decline eGFR respectively. CONCLUSION: Even high normal SUA level, was associated with the risk of hypertension, early nephropathy and decline of eGFR. Moreover SUA level may identify the onset of hypertension, early nephropathy and progression of CKD in T2DM.


Asunto(s)
Diabetes Mellitus Tipo 2/sangre , Nefropatías Diabéticas/sangre , Nefropatías Diabéticas/etiología , Hipertensión/sangre , Hipertensión/etiología , Insuficiencia Renal Crónica/sangre , Insuficiencia Renal Crónica/etiología , Ácido Úrico/sangre , Estudios de Casos y Controles , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo
3.
J. bras. nefrol ; 38(4): 403-410, Oct.-Dec. 2016. tab
Artículo en Inglés | LILACS | ID: biblio-829072

RESUMEN

Abstract Introduction: Early detection diabetic nephropathy (DN) is important. Whether serum uric acid (SUA) has a role in the development of DN is not known. Objective: To study the relationship between SUA and hypertension, early nephropathy and progression of chronic kidney disease (CKD) in type 2 diabetes mellitus (T2DM). Methods: The total number of the study was 986 participants, according to presence and duration of diabetes were classified into three groups. Group I; including 250 healthy participants. Group II; including 352 with onset of diabetes < 5 years. Group III; including 384, with the onset of diabetes > 5 years. All participants were submitted to complete clinical examination, anthropometric measurements, laboratory investigations, including glycosylated hemoglobin (HbA1C), as well triglycerides to high-density lipoprotein ratios (TG/HDL-C), SUA, urinary albumin/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR). Results: SUA, BP, HbA1c, TG/HDL-C ratio, and ACR levels were significantly higher in group III than group I, II and in II than I. eGFR significantly lower in group III than group I, II and in II than I (p < 0.001). Age, BMI, BP, HbA1c, TG/HDL-C, ACR, were positively correlated with SUA, while GFR negatively correlated. SUA at level of > 6.1 mg/dl, > 6.2 mg/dl and > 6.5 mg/dl had a greater sensitivity and specificity for identifying hypertension, early nephropathy and decline eGFR respectively. Conclusion: Even high normal SUA level, was associated with the risk of hypertension, early nephropathy and decline of eGFR. Moreover SUA level may identify the onset of hypertension, early nephropathy and progression of CKD in T2DM.


Resumo Introdução: A detecção precoce da nefropatia diabética (ND) é importante. O ácido úrico sérico (AUS) tem um papel ainda desconhecido no desenvolvimento de ND. Objetivo: Estudar a relação entre AUS e hipertensão, nefropatia precoce e progressão da doença renal crônica (DRC) no diabetes mellitus tipo 2 (DM2). Métodos: O estudo contou com 986 participantes, de acordo com a presença e a duração do diabetes, os pacientes foram classificados em três grupos. O Grupo I incluiu 250 participantes saudáveis. O Grupo II incluiu 352 pacientes com início de diabetes < 5 anos. O Grupo III incluiu 384 pacientes com o aparecimento de diabetes > 5 anos. Todos os participantes foram submetidos a exame clínico completo, medidas antropométricas, exames laboratoriais - incluindo hemoglobina glicosilada (HbA1C), bem como a razão entre triglicérides e lipoproteína de alta densidade (TG/HDL-C), AUS, razão creatinina/albumina (RCA) urinária, e taxa estimada de filtração glomerular (eTFG). Resultados: A razão AUS, PA, HbA1c, TG/HDL-C e RCA foi significativamente maior no grupo III do que no grupo I, II e em II do que I. A eTFG foi significativamente menor no grupo III do que nos grupos I, II e no II do que no I (p < 0,001). Idade, IMC, PA, HbA1c, razão TG/HDL-C, RCA, foram positivamente correlacionados com AUS, enquanto que a TFG esteve negativamente correlacionada. O AUS a níveis > 6,1 mg/dl, > 6,2 mg/dl e > 6,5 mg/dl apresentou maior sensibilidade e especificidade para identificar hipertensão, nefropatia precoce e declínio da eTFG, respectivamente. Conclusão: Mesmo elevados níveis de AUS, foi associado ao risco de hipertensão, nefropatia precoce e declínio da eTFG. Além disso, o nível de AUS pode identificar o início da hipertensão, nefropatia precoce e progressão da DRC em DM2.


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Diabetes Mellitus Tipo 2/sangre , Nefropatías Diabéticas/etiología , Nefropatías Diabéticas/sangre , Insuficiencia Renal Crónica/sangre , Hipertensión/etiología , Hipertensión/sangre , Factores de Tiempo , Ácido Úrico/sangre , Estudios de Casos y Controles , Progresión de la Enfermedad , Insuficiencia Renal Crónica/etiología
4.
Dis Markers ; 2015: 513219, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25960594

RESUMEN

BACKGROUND: Childhood cancer survivors treated with anthracyclines and mediastinal irradiation are at risk for late onset cardiotoxicity. AIMS OF THE STUDY: To assess the role of N-terminal pro-brain natriuretic peptide (NT-proBNP) and tissue Doppler imaging (TDI) as early predictors of late onset cardiotoxicity in asymptomatic survivors of childhood cancer treated with doxorubicin with or without mediastinal irradiation. METHODS: A cross-sectional study on 58 asymptomatic survivors of childhood cancer who received doxorubicin in their treatment protocols and 32 asymptomatic Hodgkin's lymphoma survivors who received anthracycline and mediastinal irradiation. Levels of NT-proBNP, TDI, and conventional echocardiography were determined. RESULTS: Thirty percent of survivors had abnormal NT-proBNP levels. It was significantly related to age at diagnosis, duration of follow-up, and cumulative dose of doxorubicin. TDI detected myocardial affection in 20% more than conventional echocardiography. Furthermore, abnormalities in TDI and NT-pro-BNP levels were more common in Hodgkin lymphoma survivors receiving both chemotherapy and radiotherapy. CONCLUSIONS: TDI could detect early cardiac dysfunction even in those with normal conventional echocardiography. Measurement of NT-proBNP represents an interesting strategy for detecting subclinical cardiotoxicity. We recommend prospective and multicenter studies to validate the role of NT-proBNP as an early marker for late onset doxorubicin-induced cardiotoxicity.


Asunto(s)
Antineoplásicos/efectos adversos , Doxorrubicina/efectos adversos , Cardiopatías/sangre , Enfermedad de Hodgkin/radioterapia , Péptido Natriurético Encefálico/sangre , Fragmentos de Péptidos/sangre , Radioterapia/efectos adversos , Biomarcadores/sangre , Cardiotoxicidad/sangre , Cardiotoxicidad/etiología , Niño , Preescolar , Femenino , Cardiopatías/etiología , Enfermedad de Hodgkin/tratamiento farmacológico , Humanos , Masculino , Sobrevivientes
5.
Auris Nasus Larynx ; 42(5): 365-8, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25794691

RESUMEN

OBJECTIVE: The aim of this study was to assess the topical use of autologous platelet rich plasma (PRP) to improve success rate of myringoplasty. METHODS: This study was carried out on 64 patients with large dry central tympanic membrane perforations. Myringoplasty was performed through postauricular approach by underlay graft using conchal perichondrial graft. Patients were classified into two groups: case group included 32 patients who had undergone myringoplasty with use of autologous PRP and control group included 32 patients who had undergone myringoplasty without use of autologous PRP. RESULTS: Both groups were statistically matched with regard to age and sex. At 6 months postoperatively, success rate (graft taking) in case group (100%) was significantly higher than in control group (81.25%) (P=0.02). Success in terms of hearing gain (≥10dB) was achieved in 21 patients (65.6%) in case group and 11 patients (34.4%) in control group with statistically non-significant difference (P=0.079). Infection rate in control group (12.5%) was found to be significantly higher than in case group (P<0.0001). CONCLUSION: Topical autologous PRP application during myringoplasty is safe and highly efficient and successful with no reported complication. PRP not only enhances healing of chronic TM perforations but also avoids infection and obviates the need for inner EAC pack.


Asunto(s)
Cartílago Auricular/trasplante , Miringoplastia/métodos , Otitis Media Supurativa/terapia , Plasma Rico en Plaquetas , Perforación de la Membrana Timpánica/terapia , Administración Tópica , Adolescente , Adulto , Niño , Femenino , Pruebas Auditivas , Humanos , Masculino , Persona de Mediana Edad , Otitis Media Supurativa/complicaciones , Resultado del Tratamiento , Perforación de la Membrana Timpánica/etiología , Cicatrización de Heridas , Adulto Joven
6.
Egypt J Immunol ; 14(2): 29-41, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-20306655

RESUMEN

Breast cancer is the most frequently diagnosed cancer in women in the world, for which tumor markers are needed for early detection, clinical prognistication and monitoring. The study was designed to assess the usefulness of HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in the diagnosis of invasive ductal carcinoma and analyze whether their levels correlate with the clinicopathological features. The study was carried out on fifty patients with invasive ductal carcinoma and 25 age matched women with benign breast diseases (BBD). Cancer patients were categorised into three subgroups according to absence (-) or presence (+) of axillary lymph nodes (N) or presence of distant metastasis (M+) into: subgroup I (N-) included 15 patients, subgroup II (N+) included 20 patients and subgroup III (M+) included 15 patients. All individuals were subjected to CBC, fasting blood sugar, liver & kidney function tests, CEA and CA15.3 by electrochemiluminescence, serum nucleosomes by cell death detection ELISA and amplification of HER-2 gene by differential PCR. The HER-2 gene PCR results were + ve in 28% of cancer patients; 20% of subgroup I, 25% of subgroup II and 40% of subgroup III, but in none of the BBD patients. HER-2 gene amplification results showed significant positive correlation with tumor grade. Serum nucleosomes showed significant increase in cancer patients as compared to that of BBD group, significant negative correlation with HER-2 gene amplification and significant positive correlation with CA15.3. Serum nucleosomes was the most sensitive marker (76% versus 32% and 50% for CEA & CA15.3 respectively) but the least specific (72% versus 92% and 96% for CEA & CA15.3 respectively). Elevated CEA and CA15.3 levels were detected in 13.3% and 33.3% respectively in node negative patients, these percentage increased in node positive patients to 20% and 40% and in metastatic patients to 66.7% and 80% respectively. In conclusion, serum nucleosomes is more sensitive but less specific marker than CEA and CA15.3 for diagnosis of early-stage breast cancer. HER-2 gene amplification is a potential prognostic marker for advanced stage breast cancer.


Asunto(s)
Neoplasias de la Mama/patología , Antígeno Carcinoembrionario/sangre , Amplificación de Genes , Genes erbB-2/genética , Mucina-1/sangre , Nucleosomas/metabolismo , Adulto , Anciano , Biomarcadores de Tumor/sangre , Neoplasias de la Mama/sangre , Neoplasias de la Mama/genética , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Valor Predictivo de las Pruebas , Pronóstico , Curva ROC
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA